The cytokine gene polymorphisms (TNF-α, IL-10 And IFN-γ) and the role of inflammatory cytokines in diabetic neuropathy

M. Ramesh, Konathala Geetha Kumari, G. Sudhakar


Background: One of the most frequently-occurring micro vascular complications is diabetic neuropathy (DN). Diabetic nephropathy (DN) affects approximately one third of people with type 1 or type 2 diabetes mellitus The objective of the study is an attempt to examine functional SNPs primarily at the position on gene of TNF-α (-308 G/A, rs 1800629), IL-10 (-1082 G/A, rs 1800896) and IFNγ (+874 A/T, rs 62559044) in order to establish their association with peripheral neuropathy patients with type 2 diabetes.

Methods: 150 cases presenting Diabetic neuropathy and 160 cases of age and sex matched healthy controls were included in the study. ARMS PCR was done for genotyping of TNF-α (-308), IL-10 (1082 G/A) and IFNγ (+874) polymorphism using allele specific primers for detection of single nucleotide polymorphisms. Analysis of the data was carried out using Epi Info 5 software. In addition, the gene frequencies were estimated and goodness of fit between the observed and expected phenotype frequencies was tested. Multifactor Dimensionality Reduction (MDR) analysis was performed to study case-control data and gene-gene interactions.

Results: The results revealed that the chi- square test for heterogeneity for IL-10 system was found to be significant (χ² = 16.2380; d.f = 2; p >0.001) between patients and controls, indicating a significant departure from the HWE. Thus, the test of association of both homogeneity and heterogeneity of IL-10 showed a significant difference, indicating an association of IL-10 with diabetic neuropathy.SNPs at position −308 promoter gene of TNF-α and IFNγ (+874) were not significantly associated with development of Diabetic Neuropathy.

Conclusion: This case-control study suggests that IL-10-1082G/G polymorphism is associated with the susceptibility to diabetic neuropathy in type 2 DM patients. IL-10 serves as an important bio marker in Indian population for their susceptibility to Diabetic Neuropathy as it may play a role in alteration of IL-10 production and the inflammatory responses.



Diabetic Neuropathy, Tumor Necrosis Factor Alpha, Interleukin – 10, Interferon Gamma

Full Text:



Christian N. Diabetes Cases Rise From 30 Million to 230 Million in 20 Years. In: Medical News Today (ed). International Diabetes Federation; 2006 (available online http://www.medicalnewstoday. com/articles/44967.php). (Retrieved on 11/6/ 2006).

Daneshmandi S, Pourfathollah A, Arababadi MK, Hassanshahi G, Rezaeian M, Asiabanha M. Evaluation of relation between IL-4 and IFN- γ polymorphisms and type 2 diabetes. Mazand Univ Med Sci.2008; 18:35-41.

Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy. Contrib Nephrol. 2011; 170: 1–7.

Wong MC, Chung WY, Wong KS. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007; (2): 1-10.

Braunwald E, Fauci AS, Kasper DL. In Harrison Principles of Internal Medicine McGraw- Hill (ed), 2001; vol 2, 15th edition. New York.

Feldman EL, Russell JW, Sullivan KA, Golovoy D. New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol. 1999; 12: 553-563.

Quasthoff S. The role of axonal ion conductances in diabetic neuropathy: a review. Muscle Nerve. 1998; 21: 1246-1255.

Martinez-Blasco A, Bosch-Morell F, Trenor C, Romero FJ. Experimental diabetic neuropathy: role of oxidative stress and mechanisms involved. Biofactors 1998; 8: 41-43.

World Health Organization. Diabetes: The Cost of Diabetes Fact Sheet #236 2002(available online (Retrieved on 12/8/2005)

Kovar and Florian M. In The Tumor Necrosis Factor [Alpha] -308 G/A Polymorphism Does Not Influence Inflammation And Coagulation Response In Human Endotoxemia. 2007; pp 238-241. Vol 27 - Issue 3.

Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995; 95, 2409–2415.

Wastowski IJ, Peres NT, Simões RT, Castelli EC, Simões AL, Martinez-Rossi NM, Donadi EA. Identification of a novel 120 bp allele at the TNFd microsatellite locus. Tissue Antigens. 2006; 67(4):318–20.

Hajeer AH, Hutchinson. Influence of TNF alpha gene polymorphisms on TNF alpha production and disease. Hum Immunol. 2001; 62: 1191–1199.

Dokter WH, Koopmans SB, Vellenga E. Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL-6, NFκB) which are involved in IL-6 regulation. Leukemia. 1996; 10: 1308.

Korholz D, Banning U, Bonig H, et al. The role of Interleukin-10 in IL-15-mediated T cell responses. Blood. 1997; 90: 4513.

Stalenhoef JE, Alisjahbana B, Nelwan EJ, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis. 2008; 27:97-103.

Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol. 2005; 100:1134–42.

Lahari DK, Bill S. DNA isolation by a rapid method from human blood samples: Effects of MgCl2, EDTA, Storage Time and Temperature on DNA yield and quality. Biochem. Genet. 1993; 31 (7&8):321-328.

Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta1 gene polymorphisms. Transpl Immunol. 1999; 7:127–8.

Balakrishnan V. Hardy-weinberg equilibrium and allele frequency estimation. In: Malhotra KC (ed) Statistical Methods in human population genetics, IBRAD, ISI and ISHG, Calcutta. 1988; pp. 39-93.

Taylor GL, Prior AM. Blood groups in England II distribution in the population. Ann Eugen. 1938; 8: 356 – 361.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 77–88.

Ritchie MD, Hahn LW, Moore JH. Power of multifactor-dimensionality reduction for detecting gene-gene in teractions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol. 2003; 24, 150–157.

Moore JH. Computational analysis of gene-gene interactions using multifactor dimensionality reduction. Expert Rev Mol Diagn 4, 795–803.

Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD (1996) Prevalence of diabetic peripheral neuropathy and its relation to glycemic control and potential risk factors. The Euro Diab IDDM complications study. Diabetologia. 2004; 39: 1377-1384.

Shiba T, Higashi N, Nishimura Y. Hyperglycemia due to in¬sulin resistance caused by interferon-gamma. Diabet Med. 1998; 15:435-6.

Yu LN, Yang XS, Hua Z and Xie W. Serum levels of pro-inflammatory cytokines in diabetic patients with peripheral neuropathic pain and the correlation among them. Zhonghua Yi Xue Za Zhi. 2009; 89: 469-471.

Gonzalez JFN and Fernandez CM. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008; 19: 433-442.

Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T and Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J. Clin. Endocrinol. Metab. 2009; 94: 2157-2163.

Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 2002; 13:299–313.

Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003; 14:185–91.

Brinkman BM, Huizinga TW, Kurba SS et al. Tumour necrosis factor a gene polymorphisms in rheumatoid arthritis: association with sus ceptibility to, or severity of, disease? Br J Rheumatol. 1997; 36:516–21.

Rood MJ, van Krugten MV, Zanelli E et al. TNF-308A and HLADR3 alleles contribute independently to susceptibility to systemic lupus er ythematosus. Arthritis Rheum. 2000; 43:129–34.

Yoon JK, Hyo-Suk L, Jung-Hwan Y et al. Association of TNF-a pro moter polymorphisms with the clearance of hepatitis B virus infection. Hum Molec Genet. 2003; 12:2541–6.

Juszczynski P, Kalinka E, Bienvenu J et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are inde pendent predictors of non-Hodgkin lymphoma outcome. Blood. 2002; 100:3037–40.

Kubaszek A, Pihlajamaki J, Komarovski V et al. Promoter polymorphisms of the TNF-α (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. – Diabetes. 2003; 52: 1872–1876.

Mascher B, Schmitt W, Csernok E, Tatsis E, Reil A, Gross WL. Polymorphisms in the tumor necrosis factor genes in Wegener’s granulomatosis. Exp Clin Immunogenet. 1997; 14:226–33.

Gencik M, Borgmann S, Zahn R, Albert E, Sitter T, Epplen JT. Immunogenetic risk factors for anti-netrophil cytoplasmic antibody (ANCA) associated systemic vasculitis. Clin Exp Immunol. 1999; 117:412.

Shiau MY, Wu CY, Huang CN, Hu S-W, Lin SJ, Chang YH. TNF-polymorphisms and type 2 diabetes mellitus in Taiwanese patients. Tissue Antigens. 2003; 61:393–7.

Kolla VK, Madhavi G et al. Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian patients with type 2 diabetes. Cytokine. 2009; 47 (3): 173-7.

Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N, Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 2001; 159, 137–144.

Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B et al. Cytokine production patterns in cervical intraepithelial neoplasia: Association with human papillomavirus infection. J Natl Cancer Inst. 1997; 89:245–50.

Urcelay E, Santiago JL, de la Calle H, Martinez A, Figueredo A, Fernandez-Arquero M. et al. Interleukin-10 polymorphisms in Spanish type 1 diabetes patients. Genes. Immun. 2004; 5, 306–309.

Reynier F, Cazalis MA, Lecoq A, Paye M, Rosa A, Durand A et al. Lack of association of IL-10 promoter gene variants with type 1 diabetes in a French population. Hum. Immunol. 2006; 67, 311–317.

Scarpelli D, Cardellini M, Andreozzi F et al. Variants of the interleukin – 10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in Caucasian Italian subjects. Diabetes. 2006; 55(5): 1529-33.

Kung WJ, Lin CC, Liu SH, Chaung HC. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technol Ther. 2010; 12(10):809-13.

Hassan Mohebbatikaljahi, Sevda Menevse1, Ilhan Yetkin and Huseyin Demirci. Study of interleukin-10 promoter region polymorphisms (−1082A/G, −819T/C and −592A/C) in type 1 diabetes mellitus in Turkish population. Journal of Genetics. 2009; Vol. 88, No. 2.

Helaly MAH, El-Sayed ZH, Megahed AE, Ibrahem EF, Afaf Alsaid, Ibrahim AA, Ahmad Settin. Association of IL-10 and IL-6 Gene Polymorphisms with Type 2 Diabetes Mellitus among Egyptian Patients. Eur J Gen Med. 2013; 10(3):158-162

Vandana AG, Carrara Henri RO, Sachs Johnny A, Hoffman Margaret, Stanczuk Grazyna A, Williamson Anna-Lise. Ethnic differences in allelic distribution of IFN-gamma in South African women but no link with cervical cancer. J Carcinogen. 2003; 2:1–8.

Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol. 2000; 61: 863–6.

Tsiavou A, Hatziagelaki E, Chaidaroglou A, Koniavitou K, Degiannis D, Raptis SA. Correlation between intracellular interferon-gamma (IFN-gamma) production by CD4+ and CD8+ lymphocytes and IFN-gamma gene polymorphism in patients with type 2 diabetes mellitus and latent autoimmune diabetes of adults (LADA). Cytokine. 2005; 31(2): 135-41.

Tamandani MKK, Sobti RC, Shekari M, Mukesh M, Suri V. Expression and polimorphism of IFN-gamma gene in patients with cervical cancer. Exp Oncol. 2008; 30:224-9.